Free Trial

iRhythm Technologies (IRTC) Stock Forecast & Price Target

iRhythm Technologies logo
$73.74 -1.73 (-2.29%)
(As of 11/20/2024 ET)

iRhythm Technologies - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
9

Based on 10 Wall Street analysts who have issued ratings for iRhythm Technologies in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 1 has given a hold rating, and 9 have given a buy rating for IRTC.

Consensus Price Target

$108.50
47.14% Upside
According to the 10 analysts' twelve-month price targets for iRhythm Technologies, the average price target is $108.50. The highest price target for IRTC is $145.00, while the lowest price target for IRTC is $78.00. The average price target represents a forecasted upside of 47.14% from the current price of $73.74.
Get the Latest News and Ratings for IRTC and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for iRhythm Technologies and its competitors.

Sign Up

IRTC Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
7 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$108.50$113.90$118.67$131.33
Forecasted Upside47.14% Upside50.68% Upside69.50% Upside51.27% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Moderate Buy

IRTC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IRTC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

iRhythm Technologies Stock vs. The Competition

TypeiRhythm TechnologiesMedical CompaniesS&P 500
Consensus Rating Score
2.90
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside47.14% Upside26,931.27% Upside9.84% Upside
News Sentiment Rating
Positive News

See Recent IRTC News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/1/2024Robert W. Baird
2 of 5 stars
 Lower TargetOutperform ➝ Outperform$100.00 ➝ $79.00+9.06%
10/31/2024Needham & Company LLC
2 of 5 stars
 Lower TargetBuy ➝ Buy$119.00 ➝ $96.00+42.54%
10/22/2024Truist Financial
2 of 5 stars
 Boost TargetBuy ➝ Buy$80.00 ➝ $95.00+27.38%
10/4/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Roman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$78.00+17.68%
9/25/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$122.00 ➝ $137.00+88.89%
8/22/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$135.00 ➝ $110.00+58.41%
8/2/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$133.00 ➝ $100.00+35.35%
8/2/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$165.00 ➝ $145.00+90.26%
7/15/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$135.00 ➝ $130.00+35.39%
6/20/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Polark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$115.00+17.16%
6/8/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$165.00 ➝ $140.00+37.34%
5/5/2023VNET Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
2/7/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$150.00+41.99%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:32 AM ET.


IRTC Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for iRhythm Technologies is $108.50, with a high forecast of $145.00 and a low forecast of $78.00.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iRhythm Technologies in the last year. There is currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IRTC shares.

According to analysts, iRhythm Technologies's stock has a predicted upside of 47.14% based on their 12-month stock forecasts.

iRhythm Technologies has been rated by research analysts at Canaccord Genuity Group, Needham & Company LLC, Robert W. Baird, The Goldman Sachs Group, and Truist Financial in the past 90 days.

Analysts like iRhythm Technologies more than other "medical" companies. The consensus rating score for iRhythm Technologies is 2.90 while the average consensus rating score for "medical" companies is 2.80. Learn more on how IRTC compares to other companies.


This page (NASDAQ:IRTC) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners